2 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 2 | Recruiting 2 |
Follow Relapse Leukemia: new trials by email Literature Review of Relapse Leukemia trials Research Report on Relapse Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Revumenib and Mezigdomide in People With Leukemia Revumenib, Mezigdomide - Leukemia, Acute Leukemia | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 52 | 2026-01-16 | 2026-10-20 |
| Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3 - Leukemia, High Risk Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 100 | 2025-03-21 | 2026-04-15 |
Leukemia (2) · Anemia, Refractory, with Excess of Blasts (1) · Bone Marrow Failure Disorders (1) · Congenital Bone Marrow Failure Syndromes (1) · Hemoglobinopathies (1) · Immunologic Deficiency Syndromes (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1) · Metabolism, Inborn Errors (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Anemia (1) · Anemia, Refractory (1) · Bone Marrow Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Infant, Newborn, Diseases (1) · Leukemia, Lymphoid (1)
Clinical Trials, Phase I as Topic (1) · revumenib (1)
Children's Hospital of Philadelphia (1) · Memorial Sloan Kettering Cancer Center (1)
United States (2)
Kuo-Kai Chin, MD (1) · Timothy Olson, MD, PhD (1)